Navigation Links
AMT to Release Half Year 2008 Results on August 13, 2008
Date:8/4/2008

AMSTERDAM, The Netherlands, August 5 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it will release its financial results for the first half year of 2008 on Wednesday, August 13, 2008 at noon Central European Time (CET). To discuss these results, the company will conduct a conference call at 2:00 p.m. CET. Netherlands dial in: 0800-949-4517 (toll free); US dial in: +1-866-291-4166 (toll free); UK dial in: +44-207-107-0611. To listen to the conference call live via the internet, visit the investor relations portion of the AMT website at http://www.amtbiopharma.com. Please go to the website 15 minutes prior to the call to register, download and install the necessary audio software.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases, especially the ones that are caused by one faulty gene. AMT currently has a product pipeline with seven products at different stages of development.


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Reminder: Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
2. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
3. Huifeng Bio-Pharmaceutical (HFGB) to Release Second Quarter 2008 Earnings Results on August 15, 2008
4. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
5. Thermage, Inc. Announces Second Quarter 2008 Results Release Date and Conference Call
6. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
7. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
8. 3SBio Inc. Schedules 2008 Second Quarter Earnings Release On Tuesday, August 12, 2008
9. NeoGenomics Schedules its Q2 2008 Earnings Release for July 31, 2008
10. American Pacific to Release Financial Results and Hold Fiscal 2008 Third Quarter Investor Teleconference
11. Zounds Hearing Develops and Releases Power BTE Hearing Aid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... N.J. , May 28, 2015  Quest Diagnostics ... of diagnostic information services, announced that it is scheduled ... in New York.  Steve Rusckowski , the company,s ... and five point strategy.  The presentation is scheduled for ... The presentation will be webcast live during ...
(Date:5/28/2015)... , May 27, 2015 Research ... of Jain PharmaBiotech,s new report "Cell Therapy ... offering. This report describes and evaluates ... started to play an important role in the ... replacing the old fashioned bone marrow transplants. Role ...
(Date:5/28/2015)... , May 28, 2015 Natera, Inc., ... a study published in Ultrasound in Obstetrics ... polymorphism (SNP)-based non-invasive prenatal test (NIPT) can identify ... A study based upon data ... pregnancies occur in about 1 in 1,000 pregnancies, ...
(Date:5/28/2015)... 2015 RXi Pharmaceuticals Corporation (NASDAQ: RXII ... innovative therapeutics, primarily in the areas of dermatology and ... of 26 million units at a price to the ... approximately $10.4 million. Each unit consists of (i) one ... right to purchase 0.50 of a share of common ...
Breaking Biology Technology:Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3
... Small Companies In America, UNION CITY, Calif., Oct. ... products company manufacturing point-of-care,blood chemistry analysis systems, announced today ... named "Entrepreneur of,the Year" by Forbes Magazine in its ... ranked eleventh of the "200 Best Small Companies in,America." ...
... Held by GlaxoSmithKline Since June 2006, PHILADELPHIA ... The Thomson Corporation (NYSE: TOC ; TSX: ... worldwide research and,business communities, today announced the availability ... on drugs and therapies. "Who is,Making the Biggest ...
... AURORA, ON, Oct. 15 /PRNewswire-FirstCall/ - Helix BioPharma Corp.,(TSX: ... F. McElroy,has resigned as Chairman and a director of ... had a long involvement with the Company since its,amalgamation ... "On behalf of the Company, I thank him for ...
Cached Biology Technology:Abaxis CEO Clint Severson Named 'Entrepreneur of the Year' by Forbes Magazine 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 3Helix BioPharma Chairman resigns 2
(Date:5/14/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ... Sensors Market in Smart Mobile Devices " report ... 2014 was a watershed year for fingerprint sensors in ... Pay,. Apple gave fingerprint sensors a raison d,etre in ... sensors are a must-have feature in flagship smartphones. ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/6/2015)... , May 6, 2015 LifeBEAM, a ... established helmet producer, announced today that they will expand ... the world,s first bio-sensing cycling helmet and the first ... in two new colors in order to give cyclists ... product. In addition, LifeBEAM and Lazer announced their plan ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... PA, May 16, 2013 The relationship between the ... not been clear. Schizophrenia is commonly associated with cognitive ... that reduced IQ may be linked to the risk ... precede the onset of schizophrenia symptoms. Also, these deficits ...
... 2013 Integrated Biometrics patented LES (Light Emitting Sensor) ... camera introduces Sherlock, a fingerprint scanner providing  the highest ... form factor available on the market today. Sherlock, an ... highly efficient and provides a 95% reduction in size ...
... 23 million years old give unprecedented insight into the ... most species-rich groups among the modern bony fishes. ... Division of Paleontology and Geobiology at the Department of ... / Germany have completed a comprehensive analysis of fish ...
Cached Biology News:Genetic risk for schizophrenia is connected to reduced IQ 2Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3
...
...
... and anti-viral agent. Inhibits several important steps of ... of HUVEC cells. Also reduces intracellular reactive oxygen ... release of endothelial cells. Formula: ... O 8 MolWeight: ...
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
Biology Products: